Department of Gastroenterology, Radboud University Medical Center, Nijmegen, The Netherlands.
Int J Oncol. 2012 Jun;40(6):1789-96. doi: 10.3892/ijo.2012.1385. Epub 2012 Feb 22.
Esophageal cancer (EC) has a globally increasing incidence with poor curative treatment options and survival rates. Environmental and dietary factors have crucial roles in esophageal carcinogenesis. Polymorphisms in the UGT genes, a superfamily of enzymes essential for the detoxification of carcinogens, may alter enzyme activity and subsequently may play a role in EC etiology. Rather than solely establishing differences in genotype distribution, we investigated whether functional polymorphisms in UGT genes that can predict enzyme activity in vivo, may influence EC risk. A case-control study including 351 Caucasian EC patients and 592 Caucasian controls was conducted and polymorphisms in seven UGT genes were determined, using the polymerase chain reaction. On the basis of allelic in vitro enzyme activity measurements, genotypes were categorized according to their predicted in vivo enzyme activity into high, medium and low categories. Predicted enzyme activity groups were combined and compared between patients and controls. The UGT1A1 and UGT1A8 predicted high enzyme activity genotypes were significantly more (OR=1.62; 95% CI, 1.02-2.56) and less frequent (OR=0.36; 95% CI, 0.15-0.84) among patients with esophageal squamous cell carcinoma (ESCC), respectively. High (OR=0.42; 95% CI, 0.22-0.84) and medium (OR=0.25; 95% CI, 0.12-0.52) activity UGT2B4 genotypes were significantly less often present in ESCC patients. No association was detected between UGT genotypes and esophageal adenocarcinoma (EAC) risk. Polymorphisms in UGT genes, resulting in altered enzyme activity genotypes, do not seem modifiers of EAC risk. However, the predicted high activity UGT1A1 genotype, associated with low serum levels of the antioxidant bilirubin, was associated with an increased ESCC risk. The UGT1A8 and UGT2B4 genotypes associated with decreased predicted enzyme activities, were significantly associated with an increased risk of ESCC, probably by a decreased detoxification of carcinogens.
食管癌(EC)的发病率在全球范围内呈上升趋势,治疗方法有限,生存率低。环境和饮食因素在食管癌的发生中起着关键作用。UGT 基因超家族的酶对于致癌物的解毒至关重要,其基因的多态性可能改变酶的活性,从而可能在 EC 的病因学中发挥作用。我们不仅要确定 UGT 基因的基因型分布差异,还要研究体内预测酶活性的功能性多态性是否会影响 EC 的风险。我们进行了一项病例对照研究,纳入了 351 例白种人食管癌患者和 592 例白种人对照,使用聚合酶链反应确定了 7 个 UGT 基因的多态性。根据体外等位基因酶活性测定,根据预测的体内酶活性将基因型分为高、中、低三类。将预测的酶活性组进行组合,并在患者和对照组之间进行比较。UGT1A1 和 UGT1A8 预测的高酶活性基因型在食管鳞状细胞癌(ESCC)患者中更为常见(OR=1.62;95%CI,1.02-2.56),频率更低(OR=0.36;95%CI,0.15-0.84)。高(OR=0.42;95%CI,0.22-0.84)和中(OR=0.25;95%CI,0.12-0.52)活性 UGT2B4 基因型在 ESCC 患者中明显较少。未发现 UGT 基因型与食管腺癌(EAC)风险之间存在关联。导致酶活性基因型改变的 UGT 基因多态性似乎不是 EAC 风险的修饰因子。然而,与低血清抗氧化剂胆红素水平相关的预测高活性 UGT1A1 基因型与 ESCC 风险增加相关。与预测酶活性降低相关的 UGT1A8 和 UGT2B4 基因型与 ESCC 风险增加显著相关,可能是由于致癌物的解毒作用降低。